PharmaceuticalsOur Pharmaceuticals division develops and manufactures drugs for the treatment of a wide range of acute and chronic diseases.
Our Pharmaceuticals division has a broad portfolio of innovative and established drugs in the fields of respiratory diseases, HIV, immunology and oncology. We are particularly leading in the areas of respiratory diseases and HIV, mainly because a large part of drug discovery spending is invested in these areas, and in two other potential areas: oncology and inflammatory immune diseases. We are strengthening our R&D pipeline through our focus on immunology, human genetics and advanced technologies. countries of all incomes-. developmental stages as accessible as possible.
The sector generated sales of 20.5 billion euros in 2021. For more than 40 years, we have played a leading role in the respiratory diseases. Have a wide range of proven products. In recent years, we have strengthened and expanded our respiratory portfolio. New drugs were added, including a combination of an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA), a long-acting muscarinic antagonist (LAMA) and a LABA double bronchodilator. In addition, a biologic for the treatment of severe eosinophilic asthma.
In addition to respiratory and HIV products, we have a portfolio of other innovative medicines for the treatment of lupus, urological and infectious diseases.
Our scientists now work in smaller groups that focus on specific research areas. The task of these groups is to investigate the biological target molecules involved in a disease and to develop new molecules or biopharmaceuticals, which eventually lead to new drugs. We are aware that we cannot make all discoveries in our own laboratories, but that partnerships with other companies, university institutions and research foundations are needed. In research, we are currently working with more than 1.500 external organizations together.
We also feel a responsibility to invest according to society's expectations in disease areas where research is difficult or the typical investment model may not be relevant. One example is our antibiotics research. We are also one of the few healthcare companies conducting research into the three diseases prioritized by the World Health Organization – HIV/AIDS, tuberculosis and malaria.
On gskpro.On the GSK website, healthcare professionals can find all GSK products, important information on the various therapeutic areas, and service content for healthcare professionals and practice teams.
Learn more about our pharmaceuticals
GSK researches extremely rare diseases, which can improve the treatment of such diseases.
Reporting side effects
Here you can report a side effect or any other (drug) safety related information.